Quick Picks - Pluristem Therapeutics (NASDAQ:PSTI) gapped down 15% Thursday morning after an announcement that the company will be raising capital through the sale of $32M in common … Continue Reading
Read nowResearch - Genzyme, a subsidiary of Sanofi (NYSE:SNY), announced Wednesday night that the FDA has approved Aubagio, its oral, once-daily treatment for Relapsing Remitting Multiple Sclerosis (RRMS). … Continue Reading
Read nowLong Ideas - Updates from two clinical trials are playing into shares of Oncolytics Biotech (NASDAQ:ONCY) Thursday morning, with some good news perking up the shares after Wednesday’s … Continue Reading
Read nowLong Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) announced Wednesday that its lead drug, Amitiza, received approval for marketing in the U.K. for chronic idiopathic constipation (CIC). This marks the … Continue Reading
Read nowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read nowQuick Picks - After the markets’ close Tuesday, Santarus Inc. (NASDAQ:SNTS) reported top-line data from a phase III trial of rifamycin SV MMX, sending shares up 6% in … Continue Reading
Read nowQuick Picks - On Wednesday morning, Opexa Therapeutics (NASDAQ:OPXA) announced the initiation of a Phase IIb trial, called Alibi-T, for Tcelna, the company’s T-cell therapy for multiple sclerosis. … Continue Reading
Read now